^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MSLN positive

    i
    Other names: MSLN, CAK1, MPF, Mesothelin
    Entrez ID:
    10232
    Related biomarkers:
    Expression
    Others
    Apply
    Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCI-2018-01503) (NCT03587311)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    10/12/2018
    Primary completion :
    10/21/2024
    Completion :
    10/21/2024
    MSLN
    |
    MSLN positive
    |
    Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Krabeva (bevacizumab biosimilar) • anetumab ravtansine (BAY 94-9343) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (NCI10208) (NCT03816358)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/16/2024
    Initiation :
    12/09/2019
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    MSLN
    |
    MSLN expression • MSLN positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • liposomal gemcitabine (FF-10832)
    A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours (NCT05804526)
    Phase 1/2
    RemeGen Co., Ltd.
    Recruiting
    Last update posted :
    04/30/2024
    Initiation :
    07/19/2023
    Primary completion :
    05/01/2025
    Completion :
    12/01/2025
    MSLN
    |
    MSLN positive
    |
    Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)
    Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (NCT03907852)
    Phase 1/2
    TCR2 Therapeutics
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    04/15/2019
    Primary completion :
    11/02/2028
    Completion :
    11/02/2028
    MSLN
    |
    MSLN expression • MSLN positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV
    A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (NCT05451849)
    Phase 1/2
    TCR2 Therapeutics
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    06/21/2022
    Primary completion :
    10/30/2028
    Completion :
    10/30/2028
    MSLN
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • TC-510
    Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin (NCT05375825)
    Phase 1
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/01/2024
    Initiation :
    02/06/2024
    Primary completion :
    12/18/2024
    Completion :
    12/18/2024
    MSLN
    |
    MSLN expression • MSLN positive
    |
    LMB-100
    Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers (NCT05779917)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    11/15/2023
    Initiation :
    03/10/2023
    Primary completion :
    03/10/2026
    Completion :
    03/10/2033
    MSLN
    |
    MSLN expression • MSLN positive
    |
    Mesothelin/GPC3/GUCY2C-CAR-T
    Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC) (NCT01393483)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    10/03/2023
    Initiation :
    03/01/2011
    Primary completion :
    09/01/2024
    Completion :
    09/01/2024
    MSLN
    |
    MSLN expression • MSLN positive
    Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (NCT04727554)
    Phase 1
    Amgen
    Completed
    Last update posted :
    09/22/2023
    Initiation :
    04/29/2021
    Primary completion :
    06/05/2023
    Completion :
    06/05/2023
    MSLN
    |
    MSLN expression • MSLN positive
    |
    inezetamab (AMG994) • zeluvalimab (AMG 404)
    Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer (NCT05686720)
    Phase 1
    First Affiliated Hospital of Shantou University...
    Not yet recruiting
    Last update posted :
    01/16/2023
    Initiation :
    02/01/2023
    Primary completion :
    02/01/2024
    Completion :
    06/01/2024
    HER-2 • ER • PGR • MSLN
    |
    HER-2 negative • ER negative • MSLN positive • PGR negative
    |
    SZ011
    Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors (NCT05141253)
    Phase 1
    Tongji Hospital
    Recruiting
    Last update posted :
    04/27/2022
    Initiation :
    01/12/2022
    Primary completion :
    11/01/2023
    Completion :
    11/01/2036
    MSLN
    |
    MSLN positive
    |
    RD133
    MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid Tumors (NCT05344976)
    Phase 1
    Peking University
    Not yet recruiting
    Last update posted :
    04/25/2022
    Initiation :
    04/14/2022
    Primary completion :
    10/14/2024
    Completion :
    02/01/2026
    EGFR • ALK • MET • ROS1 • MSLN
    |
    ALK positive • EGFR positive • EGFR negative • MSLN positive
    |
    YTS105
    An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors (NCT05166070)
    Phase 1
    The First Affiliated Hospital with Nanjing Medi...
    Recruiting
    Last update posted :
    12/21/2021
    Initiation :
    01/01/2022
    Primary completion :
    01/01/2024
    Completion :
    01/01/2037
    MSLN
    |
    MSLN positive
    |
    RD133
    Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors (Amaretto) (NCT04981691)
    Phase 1
    Ruijin Hospital
    Recruiting
    Last update posted :
    09/17/2021
    Initiation :
    10/01/2021
    Primary completion :
    01/09/2022
    Completion :
    07/09/2022
    MSLN
    |
    MSLN positive
    |
    cyclophosphamide • MSLN CAR-T • UCLM802
    The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer (NCT03814447)
    Phase 1
    Shanghai 6th People's Hospital
    Recruiting
    Last update posted :
    08/10/2021
    Initiation :
    08/16/2019
    Primary completion :
    01/01/2023
    Completion :
    01/01/2023
    MSLN
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • anti- MESO CAR-T cells • cyclophosphamide intravenous
    Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies (NCT03941626)
    Phase 1/2
    Shenzhen BinDeBio Ltd.
    Recruiting
    Last update posted :
    02/04/2021
    Initiation :
    09/01/2019
    Primary completion :
    05/01/2021
    Completion :
    12/01/2021
    HLA-A • MSLN • CTAG1B
    |
    HLA-A*02:01 • MSLN positive • HLA-A positive
    |
    cyclophosphamide • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
    Anti-ALPP CAR-T Cells Immunotherapy for Ovarian and Endometrial Cancer (NCT04627740)
    Phase 1/2
    Xinqiao Hospital of Chongqing
    Not yet recruiting
    Last update posted :
    11/13/2020
    Initiation :
    12/01/2020
    Primary completion :
    12/31/2022
    Completion :
    12/31/2023
    MSLN
    |
    MSLN positive
    |
    cyclophosphamide • TC-A101
    Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. (NCT03545815)
    Phase 1
    Chinese PLA General Hospital
    Unknown status
    Last update posted :
    08/10/2020
    Initiation :
    03/19/2018
    Primary completion :
    10/30/2020
    Completion :
    12/30/2020
    MSLN
    |
    MSLN positive
    |
    GC008t • MPTK-CAR-T cells • MSLN CAR-T
    MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer (NCT03916679)
    Phase 1/2
    Second Affiliated Hospital, School of Medicine,...
    Recruiting
    Last update posted :
    04/16/2019
    Initiation :
    04/20/2019
    Primary completion :
    04/20/2022
    Completion :
    04/20/2023
    MSLN
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV
    MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer (NCT03799913)
    Phase 1
    Zhejiang University
    Unknown status
    Last update posted :
    04/10/2019
    Initiation :
    04/10/2019
    Primary completion :
    10/01/2021
    Completion :
    04/01/2022
    MSLN
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • anti- MESO CAR-T cells
    Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer (NCT03692637)
    Phase 1
    Allife Medical Science and Technology Co., Ltd.
    Unknown status
    Last update posted :
    01/31/2019
    Initiation :
    03/01/2019
    Primary completion :
    11/01/2020
    Completion :
    11/01/2021
    PD-L1 • PD-1 • MSLN
    |
    MSLN expression • MSLN positive
    |
    MSLN CAR-T • anti-Mesothelin CAR NK Cells
    Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors (NCT03747965)
    Phase 1
    Chinese PLA General Hospital
    Unknown status
    Last update posted :
    11/20/2018
    Initiation :
    11/01/2018
    Primary completion :
    11/01/2019
    Completion :
    05/01/2020
    MSLN
    |
    MSLN positive
    |
    paclitaxel • cyclophosphamide • GC008t
    PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies (NCT03030001)
    Phase 1/2
    Ningbo Cancer Hospital
    Unknown status
    Last update posted :
    01/24/2017
    Initiation :
    02/15/2017
    Primary completion :
    12/01/2018
    Completion :
    02/01/2019
    MSLN
    |
    MSLN positive
    Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors (NCT02930993)
    Phase 1
    China Meitan General Hospital
    Unknown status
    Last update posted :
    10/12/2016
    Initiation :
    08/01/2016
    Primary completion :
    08/01/2018
    Completion :
    08/01/2019
    MSLN
    |
    MSLN positive
    |
    cyclophosphamide • MSLN CAR-T • anti-mesothelin CAR T cells
    A Study of MORAb-009 in Patients With Solid Tumor (MORAB-009-J081-102) (NCT01018784)
    Phase 1
    Eisai Co., Ltd.
    Completed
    Last update posted :
    01/21/2016
    Initiation :
    11/01/2009
    Primary completion :
    05/01/2012
    Completion :
    02/01/2013
    MSLN
    |
    MSLN positive
    |
    amatuximab (MORAb-009)
    Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso (NCT02580747)
    Phase 1
    Chinese PLA General Hospital
    Unknown status
    Last update posted :
    10/20/2015
    Initiation :
    10/01/2015
    Primary completion :
    11/01/2017
    Completion :
    11/01/2018
    MSLN
    |
    MSLN positive